The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Eledon Pharmaceuticals Inc (NASDAQ: ELDN) closed at $2.6 up 1.96% from its previous closing price of $2.55. In other words, the price has increased by $1.96 from its previous closing price. On the day, 1.1 million shares were traded. ELDN stock price reached its highest trading level at $2.66 during the session, while it also had its lowest trading level at $2.53.
Ratios:
For a deeper understanding of Eledon Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.12 and its Current Ratio is at 8.12. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELDN now has a Market Capitalization of 155692608 and an Enterprise Value of 104917336.
Stock Price History:
The Beta on a monthly basis for ELDN is 0.40, which has changed by 0.03174603 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, ELDN has reached a high of $5.54, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is -11.01%, while the 200-Day Moving Average is calculated to be -25.01%.
Shares Statistics:
For the past three months, ELDN has traded an average of 852.06K shares per day and 818770 over the past ten days. A total of 59.88M shares are outstanding, with a floating share count of 55.83M. Insiders hold about 6.76% of the company’s shares, while institutions hold 64.16% stake in the company. Shares short for ELDN as of 1756425600 were 4342922 with a Short Ratio of 5.10, compared to 1753920000 on 4373776. Therefore, it implies a Short% of Shares Outstanding of 4342922 and a Short% of Float of 8.1099994.
Earnings Estimates
The stock of Eledon Pharmaceuticals Inc (ELDN) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.17 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.49 and -$1.26 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$1.12, with 4.0 analysts recommending between -$0.97 and -$1.31.
